Cellectar Biosciences announced positive 12-month follow-up results from its Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia, showing an 83.6% overall response rate and median response duration of 17.8 months. The data meet FDA requirements for accelerated approval and support a confirmatory trial planned for late 2026. The drug showed strong efficacy in patients previously treated with BTK inhibitors, a difficult-to-treat group, and maintained a manageable safety profile. This progress positions iopofosine I 131 as a promising new treatment option for heavily pretreated WM patients with limited alternatives.
Following Shell's interim dividend payment for Q1 2026 on June 29, several senior executives, including CEO Wael Sawan and CFO Sinead Gorman, acquired shares through dividend reinvestment plans. These shares were obtained in respect of shares previou...
The global aliphatic hydrocarbon solvents and thinners market is projected to grow from $5.26 billion in 2026 to $6.81 billion by 2032, at a CAGR of 4.4%. Growth is fueled by rising demand in coatings, adhesives, and industrial maintenance, with mine...
The global data center semiconductor market is projected to grow from $86.8 billion in 2024 to $265.8 billion by 2029, driven by rising demand for AI-powered servers. The power stage segment will dominate due to its critical role in efficient power d...
The data center direct-to-chip cooling market is projected to grow from $3.33 billion in 2026 to $17.31 billion by 2032, at a CAGR of 26.5%. This growth is driven by the need for precise thermal management in advanced computing, especially for edge c...
The global environmental DNA (eDNA) market is projected to expand from $1.63 billion in 2026 to $5.61 billion by 2031, growing at a 10.2% CAGR. This growth is driven by advanced, non-invasive testing methods that detect species through genetic materi...
